Clinical Edge Journal Scan

Allergic contact dermatitis a crucial comorbidity in atopic dermatitis


 

Key clinical point : Allergic contact dermatitis (ACD) is an important comorbidity in patients with atopic dermatitis (AD) and leads to the maintenance and aggravation of their dermatosis, with a high frequency of ACD observed to textile dyes, isothiazolinones, and fragrances.

Major finding: Contact sensitization was significantly associated with facial involvement ( P = .04) and a longer duration of AD ( P = .005). The most frequent allergen was textile dye mix (24.70%) followed by nickel (20.21%), cobalt (12.70%), and methylchlorisothiazolinone+methylisothiazolinone (8.50%). The avoidance of relevant allergens led to a significant reduction in the Scoring of Atopic Dermatitis (SCORAD) scores at 6 months ( P < .001).

Study details: This longitudinal prospective study included 93 patients with AD (age > 2 years) who were patch-tested with the 2019 European baseline series and the corticosteroid series, 60.2% of whom had positive patch test results.

Disclosures: This study did not disclose any funding source. The authors declared no conflicts of interest.

Source: Trimeche K et al. Contact allergy in atopic dermatitis: A prospective study on prevalence, incriminated allergens and clinical insights. Contact Dermatitis. 2023 (Dec 27). doi: 10.1111/cod.14494

Recommended Reading

Experimental Topical Drug Shows Promise for Atopic Dermatitis and Plaque Psoriasis
MDedge Dermatology
Which Tools Are Best to Streamline In-Office Assessments of Eczema Patients?
MDedge Dermatology
US Dermatologic Drug Approvals Rose Between 2012 and 2022
MDedge Dermatology
Expert Highlights Biologics in the Pipeline for Atopic Dermatitis
MDedge Dermatology
AAAAI/ACAAI Joint Task Force Issues Updated ‘Practice-Changing’ Guidelines to Manage AD
MDedge Dermatology
Atopic dermatitis not linked with increased venous thromboembolism risk
MDedge Dermatology
Atopic dermatitis not linked with increased venous thromboembolism risk
MDedge Dermatology
Interim analysis confirms the safety and efficacy of dupilumab in atopic dermatitis
MDedge Dermatology
Rademikibart shows promise in moderate-to-severe atopic dermatitis
MDedge Dermatology
Aggregate response benefit in skin clearance and itch reduction favor upadacitinib over dupilumab in AD
MDedge Dermatology